NASDAQ$NUVL
Nuvalent Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Nuvalent made significant progress across its pipeline of novel kinase inhibitors and reported fourth quarter and full year 2022 financial results.
Nuvalent reported a strong financial position with $472.2 million in cash, cash equivalents and marketable securities, which is expected to fund operations into the second half of 2025. The company highlighted progress in its clinical trials for NVL-520 and NVL-655 and the nomination of NVL-330 as a third development candidate.
- Presented preliminary Phase 1 data supportive of the potential best-in-class profile of NVL-520 as a brain-penetrant, ROS1-selective inhibitor.
- Initiated clinical development with NVL-655, a brain penetrant, ALK-selective inhibitor, in the Phase 1 portion of its ongoing ALKOVE-1 Phase 1/2 study.
- Declared a third development candidate, NVL-330, a novel HER2-selective inhibitor for patients with HER2 exon 20 insertion-positive cancers.
- Cash, cash equivalents and marketable securities were $472.2 million as of December 31, 2022, expected to fund operations into the second half of 2025.
Headline financials
Revenue & EPS history
Nuvalent · Revenue · Quarterly
$6M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2022
-0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-7.7%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+14.6%
Q4 2021
Best reaction
-5.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.5% | -4.1% | -7.5% | |
| Q3 2025 | -5.0% | -11.6% | +6.2% | |
| Q1 2025 | +3.2% | +3.7% | +10.2% | |
| Q4 2024 | -2.8% | -7.0% | -5.2% | |
| Q3 2024 | -4.3% | -8.0% | -8.0% | |
| Q1 2024 | -3.1% | +0.7% | +17.2% | |
| Q4 2023 | -1.4% | +0.6% | -13.3% | |
| Q3 2023 | +3.7% | +5.0% | +38.8% | |
| Q2 2023 | -1.1% | -3.1% | +9.2% | |
| Q1 2023 | -2.5% | -1.1% | +3.5% | |
| Q4 2022 | +8.3% | +4.7% | +0.9% | |
| Q3 2022 | +1.0% | +2.9% | -2.1% | |
| Q2 2022 | +4.5% | +9.3% | +13.1% | |
| Q1 2022 | -0.7% | +7.3% | +16.1% | |
| Q4 2021 | +14.6% | +20.2% | -8.1% | |
| Q3 2020 | +1.3% | -14.7% | -2.4% | |
| Q3 2021 | +1.3% | -10.4% | -20.1% | |
| Q2 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2021 | -4.3% | -2.9% | -52.6% | |
| Q2 2021 | -4.3% | -2.9% | -52.6% | |
| Q4 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro